Companies T-Therapeutics

Unlocking the power of T cell biology


T cells are an important part of the immune system, playing a critical role in the response to infected, foreign or altered cells.

Whilst tumours originate from healthy cells, by the time they are cancerous they have changed so much that our immune systems can recognise them as different if only it is directed to look for them. Based on pioneering work by professor Allan Bradley from the Wellcome Sanger Institute and the University of Cambridge, T-Therapeutics is developing soluble T-cell receptor (TCR) therapies to target and direct T cells to the site of cancer for therapeutic treatment.

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More